Delisting riskPopularity #4,581
Gelteq (GELS)
Customizable ingestible gels for partner-branded health and animal-health products.
$0.5751
After hours−0.02 (−3.39%)
At close$0.5953(+4.24%)
In millions of USD, except per-share figures · converted from AUD at the latest rate
| In millions | Q4 FY21Jun 2021 | Q4 FY22Jun 2022 | Q4 FY23Jun 2023 | Q3 FY24Mar 2024 | Q4 FY24Jun 2024 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 1 | 7 | 1 | 1 | 1 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 1 | 0 | 0 | 1 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Operating income | 0 | −1 | −1 | −7 | −1 | −1 | −1 |
| 0 | 0 | 0 | 7 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −7 | 0 | 0 | 0 |
| Income before tax | 0 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | −1 | −1 | −1 | −1 | −1 | −1 |
| Net income | 0 | −1 | −1 | −1 | −1 | −1 | −1 |
| EPS, basic | −$0.02 | −$0.09 | $0.00 | $0.00 | $0.00 | −$0.13 | −$0.13 |
| EPS, diluted | −$0.02 | −$0.09 | $0.00 | $0.00 | $0.00 | −$0.13 | −$0.13 |
| Weighted average shares, basic | 9 | 9 | 0 | 0 | 0 | 10 | 10 |
| Weighted average shares, diluted | 9 | 9 | 0 | 0 | 0 | 10 | 10 |
| EBITDA | 0 | −1 | 0 | 0 | 0 | −1 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | −1 | −1 | 0 | −1 | −1 | −1 |